Clinical Trial Detail

NCT ID NCT02621021
Title A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Pembrolizumab

Cyclophosphamide

Fludarabine

Aldesleukin

Age Groups: adult

No variant requirements are available.